- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
5
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
5 companies
InSilico Medicine Cayman TopCo
Market Cap: HK$23.7b
Engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
3696
HK$39.42
7D
-14.3%
1Y
n/a
CanSino Biologics
Market Cap: HK$10.7b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$23.34
7D
-5.4%
1Y
-50.8%
Innovent Biologics
Market Cap: HK$168.3b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$98.25
7D
2.8%
1Y
3.8%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$62.1b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$60.45
7D
-9.9%
1Y
169.9%
WuXi XDC Cayman
Market Cap: HK$88.5b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$68.05
7D
6.5%
1Y
18.0%